Qiagen N.V.QGEN

QIAGEN’s strongest current proof is the filed 2025 annual base: $2.09B of revenue from contracts with customers, $424.9M of net income attributable to parent, $465.9M of operating income, and diluted EPS of $1.94 for the 20-F period ending 2025-12-31. The company also filed a 6-K on 2026-05-08, a Form SD on 2026-06-01, and a Schedule 13G/A on 2026-06-05, giving the daily file a current SEC EDGAR trail rather than a loose market anecdote.

QIAGEN is being read here as an operating diagnostics and life-sciences company, not as a ticker floating free of the lab. The official product rail names automated nucleic acid purification through QIAsymphony Connect, TB infection detection through QuantiFERON-TB Gold Plus kits, and solutions for laboratory-developed tests including extraction kits, PCR enzymes and instruments. That matters because the financial story is tied to clinical and research workflows, where product reliability, documentation, automation and repeat purchasing carry more weight than a neat slogan.

The latest supplied filed financials show assets of $6.28B, stockholders’ equity attributable to parent of $3.78B, cash and cash equivalents of $839.0M, short-term investments of $259.9M, net cash provided by operating activities of $654.3M, payments to acquire property, plant and equipment of $201.0M, inventory, net, of $301.9M, and diluted weighted average shares outstanding of 218.9M for the 20-F period ending 2025-12-31. Those numbers support a cash-generative business file, while the 2026-05-08 6-K adds a necessary caution that adjusted non-GAAP measures supplement the view and that excluded items significantly affect GAAP results.

The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The market mechanism that can be traced is simpler: filed annual profitability and cash, current SEC filing activity, and official product pages that prove what QIAGEN is selling into laboratory workflows. The evidence supports a company story, not a technical trade story.

What changed in the current source pack is the mix of fresh filings and product context. The QIAsymphony Connect page says shipments are expected to begin after July 2026, which creates a dated product marker without proving volumes. The QuantiFERON-TB Gold Plus webshop proves an ordering and documentation route for TB infection detection kits. The laboratory-developed-test page proves a broader support rail for in-house IVD testing. What remains unproven is adoption, price, margin, installed base, and any product-level contribution to the filed numbers.